HIGHLIGHTS
SUMMARY
A reduction in death from cardiovascular causes and heart failure hospitalization by vericiguat therapy over placebo was demonstrated in patients with heart failure with reduced ejection fraction (HFrEF) accompanying a high risk of worsening heart failure in the VICTORIA trial. The number of patients receiving SGLT2 inhibitors in the VICTORIA trial was relatively small, and the efficacy and safety of vericiguat therapy in patients receiving "quadruple therapy" including SGLT2 inhibitors, a gold standard medical strategy for patients with J. Clin. The number of patients receiving SGLT2 inhibitors in the VICTORIA trial was relatively small . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.